Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo.

Poston GJ, Yao CZ, Upp JR Jr, Alexander RW, Townsend CM Jr, Thompson JC

Pancreas1 Jan 1988Cited by 15 (Europe PMC)

PMID3174607DOI10.1097/00006676-198808000-00012PepBankPUB-03174607

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Safety outcome
In hamsters and in mice, VIP treatment had no effect on body weight.
In plain wordsIn hamsters and mice, VIP treatment did not change body weight.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeBody weight in hamsters and mice
Study
hamster and mousen = 38
H2T hamsters and MIA athymic mice
Comparator
0.1% BSA in saline
Outcome group
Adverse events · Whole body
Studied dose
1 and 10 nmol/kg in hamsters; 1 nmol/kg in mice · intraperitoneal · 35 days in hamsters; 3 months in miceAs given in this study (hamster and mouse).
Source sentences
Summary
Treatment with VIP did not have any effect on body weight or size of the normal pancreas in either the hamsters or the mice.
Report a problemFND-0317460707
02AnimalAnimal study (in vivo)Safety outcome
In hamsters and in mice, VIP treatment had no effect on the size of the normal pancreas.
In plain wordsIn hamsters and mice, VIP treatment did not change the size of the normal pancreas.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeSize of normal pancreas in hamsters and mice
Study
hamster and mousen = 38
H2T hamsters and MIA athymic mice
Comparator
0.1% BSA in saline
Outcome group
Adverse events · Whole body
Studied dose
1 and 10 nmol/kg in hamsters; 1 nmol/kg in mice · intraperitoneal · 35 days in hamsters; 3 months in miceAs given in this study (hamster and mouse).
Source sentences
Summary
Treatment with VIP did not have any effect on body weight or size of the normal pancreas in either the hamsters or the mice.
Report a problemFND-0317460708
03AnimalAnimal study (in vivo)Efficacy outcome
In athymic mice with MIA human pancreatic carcinoma, VIP at 1 nmol/kg for 3 months did not change tumor growth rate versus control.
In plain wordsIn mice with human pancreatic cancer, VIP did not change how fast the tumors grew compared with control.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeMIA human pancreatic tumor growth rate
Study
mousen = 20
MIA human pancreatic carcinoma in athymic Balb/c mice
Comparator
0.1% BSA in saline
Outcome group
Tumor growth · Cancer
Studied dose
1 nmol/kg · intraperitoneal · 3 monthsAs given in this study (mouse).
Source sentences
Summary
There was no difference in tumor growth rate between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
The growth of MIA was studied in athymic Balb/c mice, one group of 10 received 0.1% BSA and the other 10 received VIP (1 nmol/kg), both three times a day by i.p. injection for 3 months.
Report a problemFND-0317460706
04AnimalAnimal study (in vivo)Efficacy outcome
In hamsters with H2T pancreatic carcinoma, VIP at 1 and 10 nmol/kg inhibited tumor growth, measured as tumor area.
In plain wordsIn hamsters with pancreatic cancer, VIP reduced tumor growth measured as tumor area.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseH2T tumor area
Study
hamstern = 18
H2T pancreatic ductal carcinoma
Comparator
0.1% BSA in saline
Outcome group
Tumor growth · Cancer
Studied dose
1 and 10 nmol/kg · intraperitoneal · 35 daysAs given in this study (hamster).
Source sentences
Summary
Both doses of VIP inhibited the growth of H2T tumor (tumor area, weight, DNA, RNA, and protein content).
1 context sentence(design, population, supporting numbers)
Summary · context
The growth of H2T was studied in hamsters; a control group of six hamsters received 0.1% bovine serum albumin (BSA) in saline, and two treatment groups of six hamsters each received VIP (1 and 10 nmol/kg), all administered three times a day by i.p. injection for 35 days.
Report a problemFND-0317460701
05AnimalAnimal study (in vivo)Efficacy outcome
In hamsters with H2T pancreatic carcinoma, VIP at 1 and 10 nmol/kg inhibited tumor growth, measured as tumor weight.
In plain wordsIn hamsters with pancreatic cancer, VIP reduced tumor growth measured as tumor weight.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseH2T tumor weight
Study
hamstern = 18
H2T pancreatic ductal carcinoma
Comparator
0.1% BSA in saline
Outcome group
Tumor growth · Cancer
Studied dose
1 and 10 nmol/kg · intraperitoneal · 35 daysAs given in this study (hamster).
Source sentences
Summary
Both doses of VIP inhibited the growth of H2T tumor (tumor area, weight, DNA, RNA, and protein content).
1 context sentence(design, population, supporting numbers)
Summary · context
The growth of H2T was studied in hamsters; a control group of six hamsters received 0.1% bovine serum albumin (BSA) in saline, and two treatment groups of six hamsters each received VIP (1 and 10 nmol/kg), all administered three times a day by i.p. injection for 35 days.
Report a problemFND-0317460702
06AnimalAnimal study (in vivo)Efficacy outcome
In hamsters with H2T pancreatic carcinoma, VIP at 1 and 10 nmol/kg inhibited tumor growth, measured as tumor DNA content.
In plain wordsIn hamsters with pancreatic cancer, VIP lowered tumor DNA content.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseH2T tumor DNA content
Study
hamstern = 18
H2T pancreatic ductal carcinoma
Comparator
0.1% BSA in saline
Outcome group
Tumor growth · Cancer
Studied dose
1 and 10 nmol/kg · intraperitoneal · 35 daysAs given in this study (hamster).
Source sentences
Summary
Both doses of VIP inhibited the growth of H2T tumor (tumor area, weight, DNA, RNA, and protein content).
1 context sentence(design, population, supporting numbers)
Summary · context
The growth of H2T was studied in hamsters; a control group of six hamsters received 0.1% bovine serum albumin (BSA) in saline, and two treatment groups of six hamsters each received VIP (1 and 10 nmol/kg), all administered three times a day by i.p. injection for 35 days.
Report a problemFND-0317460703
07AnimalAnimal study (in vivo)Efficacy outcome
In hamsters with H2T pancreatic carcinoma, VIP at 1 and 10 nmol/kg inhibited tumor growth, measured as tumor RNA content.
In plain wordsIn hamsters with pancreatic cancer, VIP lowered tumor RNA content.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseH2T tumor RNA content
Study
hamstern = 18
H2T pancreatic ductal carcinoma
Comparator
0.1% BSA in saline
Outcome group
Tumor growth · Cancer
Studied dose
1 and 10 nmol/kg · intraperitoneal · 35 daysAs given in this study (hamster).
Source sentences
Summary
Both doses of VIP inhibited the growth of H2T tumor (tumor area, weight, DNA, RNA, and protein content).
1 context sentence(design, population, supporting numbers)
Summary · context
The growth of H2T was studied in hamsters; a control group of six hamsters received 0.1% bovine serum albumin (BSA) in saline, and two treatment groups of six hamsters each received VIP (1 and 10 nmol/kg), all administered three times a day by i.p. injection for 35 days.
Report a problemFND-0317460704
08AnimalAnimal study (in vivo)Efficacy outcome
In hamsters with H2T pancreatic carcinoma, VIP at 1 and 10 nmol/kg inhibited tumor growth, measured as tumor protein content.
In plain wordsIn hamsters with pancreatic cancer, VIP lowered tumor protein content.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseH2T tumor protein content
Study
hamstern = 18
H2T pancreatic ductal carcinoma
Comparator
0.1% BSA in saline
Outcome group
Tumor growth · Cancer
Studied dose
1 and 10 nmol/kg · intraperitoneal · 35 daysAs given in this study (hamster).
Source sentences
Summary
Both doses of VIP inhibited the growth of H2T tumor (tumor area, weight, DNA, RNA, and protein content).
1 context sentence(design, population, supporting numbers)
Summary · context
The growth of H2T was studied in hamsters; a control group of six hamsters received 0.1% bovine serum albumin (BSA) in saline, and two treatment groups of six hamsters each received VIP (1 and 10 nmol/kg), all administered three times a day by i.p. injection for 35 days.
Report a problemFND-0317460705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.